An informational resource for healthcare professionals interested in stroke reduction, venous protection, and vascular protection. Stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events through the many resources found in the tabs listed here.
Educational resources about reducing stroke by understanding the underlying thrombotic risk in patients with or without atrial fibrillation.
Educational resources about the underlying thrombotic risk of major adverse cardiac events in patients with vascular diseases such as Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Heart Failure.
Describing the various lifestyle interventions available to improve outcomes among patients with CAD and/or PAD.
Describe how physicians manage cardiovascular risk, including therapies to reduce cholesterol, manage blood pressure, and reduce thromotic risk, as well as lifestyle changes such as smoking cessation, diet and exercise.
Describing and explaining the increased risk relationship between diabetes and CAD/PAD, including how diabetes impacts the vascular system, endothelial function and platelets.
Describing the role of chronic, systemic inflammation and its on patients with CAD and/or PAD, as well as the interaction between inflammation and smoking, inflammation and lipids.
Coronary artery disease (CAD) is a common comorbidity among patients with severe peripheral artery disease (PAD), and further complicates a patient's cardiovascular health. Both CAD and severe PAD are known determinants of major adverse cardiovascular events (MACE). Assessing MACE in patients with severe PAD and CAD remains a challenge due to the complex nature of both diseases.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.